

Differential development of antibiotic resistance and virulence between *Acinetobacter* species

Darby, Elizabeth M; Moran, Robert A; Holden, Emma; Morris, Theresa; Harrison, Freya; Clough, Barbara; McInnes, Ross S; Schneider, Ludwig; Frickel, Eva M; Webber, Mark A; Blair, Jessica M A

DOI:

[10.1128/msphere.00109-24](https://doi.org/10.1128/msphere.00109-24)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Darby, EM, Moran, RA, Holden, E, Morris, T, Harrison, F, Clough, B, McInnes, RS, Schneider, L, Frickel, EM, Webber, MA & Blair, JMA 2024, 'Differential development of antibiotic resistance and virulence between *Acinetobacter* species', *mSphere*. <https://doi.org/10.1128/msphere.00109-24>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Differential development of antibiotic resistance and virulence between *Acinetobacter* species

Elizabeth M. Darby,¹ Robert A. Moran,¹ Emma Holden,² Theresa Morris,³ Freya Harrison,⁴ Barbara Clough,¹ Ross S. McInnes,¹ Ludwig Schneider,³ Eva M. Frickel,¹ Mark A. Webber,^{2,5} Jessica M. A. Blair¹

AUTHOR AFFILIATIONS See affiliation list on p. 17.

ABSTRACT The two species that account for most cases of *Acinetobacter*-associated bacteremia in the United Kingdom are *Acinetobacter lwoffii*, often a commensal but also an emerging pathogen, and *Acinetobacter baumannii*, a well-known antibiotic-resistant species. While these species both cause similar types of human infection and occupy the same niche, *A. lwoffii* (unlike *A. baumannii*) has thus far remained susceptible to antibiotics. Comparatively little is known about the biology of *A. lwoffii*, and this is the largest study on it conducted to date, providing valuable insights into its behaviour and potential threat to human health. This study aimed to explain the antibiotic susceptibility, virulence, and fundamental biological differences between these two species. The relative susceptibility of *A. lwoffii* was explained as it encoded fewer antibiotic resistance and efflux pump genes than *A. baumannii* (9 and 30, respectively). While both species had markers of horizontal gene transfer, *A. lwoffii* encoded more DNA defense systems and harbored a far more restricted range of plasmids. Furthermore, *A. lwoffii* displayed a reduced ability to select for antibiotic resistance mutations, form biofilm, and infect both *in vivo* and *in vitro* models of infection. This study suggests that the emerging pathogen *A. lwoffii* has remained susceptible to antibiotics because mechanisms exist to make it highly selective about the DNA it acquires, and we hypothesize that the fact that it only harbors a single RND system restricts the ability to select for resistance mutations. This provides valuable insights into how development of resistance can be constrained in Gram-negative bacteria.

IMPORTANCE *Acinetobacter lwoffii* is often a harmless commensal but is also an emerging pathogen and is the most common cause of *Acinetobacter*-derived bloodstream infections in England and Wales. In contrast to the well-studied and often highly drug-resistant *A. baumannii*, *A. lwoffii* has remained susceptible to antibiotics. This study explains why this organism has not evolved resistance to antibiotics. These new insights are important to understand why and how some species develop antibiotic resistance, while others do not, and could inform future novel treatment strategies.

KEYWORDS antibiotic resistance, virulence, efflux pumps, Gram-negative bacteria, drug-resistance evolution

Acinetobacter spp. are Gram-negative, soil-dwelling Gammaproteobacteria. Despite being typically found in soil, some species within the genus also cause life-threatening human infections (1). The most clinically significant of these is *Acinetobacter baumannii*, which is often highly multidrug resistant (2, 3).

According to United Kingdom Health Security Agency (UKHSA), in England, the most common cause of *Acinetobacter*-derived bacteremia is *Acinetobacter lwoffii* followed by *A. baumannii* (30% and 21%, respectively) (4). In intensive care units, the rate of *Acinetobacter* infections varies from 19.2% in Asia to 3.7% in North America, although

Editor Paul D. Fey, University of Nebraska Medical Center College of Medicine, Omaha, Nebraska, USA

Address correspondence to Jessica M. A. Blair, j.m.a.blair@bham.ac.uk.

The authors declare no conflict of interest.

See the funding table on p. 17.

Received 10 February 2024

Accepted 13 March 2024

Published 5 April 2024

Copyright © 2024 Darby et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

species-level epidemiology data are uncommon (5). *A. lwoffii* is found both in soil environments and as a common commensal of human skin (6). As well as causing bacteremia in adults, *A. lwoffii* can cause a variety of infections, often in immunocompromised hosts, and is a common cause of serious neonatal infections, which can lead to sepsis (7–10).

Both *A. lwoffii* and *A. baumannii* are found in hospitals and are resistant to desiccation, irradiation, and biocides (11, 12). However, *A. lwoffii* is generally antibiotic susceptible, in contrast to the multidrug resistance displayed by *A. baumannii* (4). There are few studies aimed at understanding *A. lwoffii*, and the reasons for its comparative sensitivity are not known.

We recently showed that the number of resistance nodulation division (RND) pumps present across the *Acinetobacter* genus varies and that *A. lwoffii* encodes fewer efflux pumps from the RND family than *A. baumannii* (1). These efflux pumps are important mediators of antibiotic resistance, suggesting that their absence may contribute to the difference in susceptibility to antibiotics (13). RND pumps have also been implicated in virulence and biofilm formation (14, 15).

In this study, we investigated the genomic and phenotypic differences between a range of *A. baumannii* and *A. lwoffii* strains (including clinical and type strains) to understand why two closely related species have such different responses to antibiotics. This study provides insight into the development of antibiotic resistance and differences in biology and virulence in two clinically important pathogens.

MATERIALS AND METHODS

Strains used in this study

Reference strains of *A. baumannii* AYE and *A. lwoffii* NCTC 5867 were used. In addition, representative clinical and non-clinical strains that were available to us were used in this study (listed in Table S1). All strains were cultured in lysogeny broth (LB) (Sigma) unless stated otherwise at 37°C.

Measurement of the susceptibility to antimicrobials

The minimum inhibitory concentration (MIC) of various antimicrobials to *A. baumannii* and *A. lwoffii* was determined using the agar dilution method (16) according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (17). Antimicrobials tested included ampicillin (Sigma #A9393), cefotaxime (Fisher #10084487), chloramphenicol (Fisher #10368030), ciprofloxacin (Fisher #13531640), clindamycin (Generon #A10227), erythromycin (Fisher #10338080), fusidic acid (Sigma #F0881), gentamicin (Fisher #10224873), meropenem (TCI Chemicals #M2279), novobiocin (Fisher #15403619), rifampicin (Fisher #10533325), and tetracycline (Fisher #10460264).

Biofilm formation and susceptibility

The ability of *A. baumannii* and *A. lwoffii* to establish monospecies biofilms and the susceptibility of these biofilms to different compounds were tested. The full methods can be found in supplemental Text S1.

Whole-genome sequence analysis

All available *A. lwoffii* and *A. baumannii* whole-genome sequences were downloaded from the National Center for Biotechnology Information (NCBI) (41 and 6,127, respectively) on 20 March 2022. In addition, laboratory strains of both *A. baumannii* (10) and *A. lwoffii* (8) were whole genome sequenced using Illumina platforms and assembled using SPAdes (18) (MicrobesNG, UK). A list of strains sequenced in this study and their assembly accession numbers can be found in Table S2.

Quast (v.5.0.2) was used to quality check (QC) sequences and those with N50 values of <30,000 and >165 Ns per kbp were removed (19). FastANI (v.1.31) was used

to determine average nucleotide identity of *A. baumannii* sequences to *A. baumannii* AYE (CU459141.1) and *A. lwoffii* sequences to *A. lwoffii* 5867 (GCA_900444925.1), and only sequences >95.5% were kept (20). MASH (v.2.2.2) (21) was also performed to identify any duplicate assemblies, which were then removed using a custom R script (<https://github.com/C-Connor/MashDistDeReplication/blob/master/MashDistDeReplication.R>). The final quality step was CheckM (v.1.1.3) (22), where sequences with >5% contamination and/or <95% completeness were removed. The final numbers of *A. baumannii* and *A. lwoffii* sequences were 4,809 and 38, respectively.

Assemblies were searched for antibiotic resistance genes (ARGs) [Comprehensive Antibiotic Resistance Database (23)], type IV pilus genes [“twitching” database using reference (24)], plasmid *rep* genes [database from reference (25)], and virulence and biofilm genes [“vandb” database using reference (26)] using ABRicate (v.0.8.13). The twitching and vandb databases can be found at <https://github.com/emd803/Gene-Databases/tree/main>. Prophages were identified in 10 random isolates of *A. baumannii* and *A. lwoffii* using PHASTER, and DNA defense systems were searched in all the genomes using DefenseFinder (v.1.0.9) (27, 28).

Selection for resistance to meropenem, ciprofloxacin, and gentamicin

To determine if *A. baumannii* (AB18) and *A. lwoffii* (AL28) could evolve resistance to three clinically relevant drugs, a selection experiment was set up using strains clinically susceptible to all three selection antibiotics. Briefly, a single colony was inoculated into 5 mL of nutrient broth (Sigma), and a 1% transfer was passaged every 24 hours in increasing concentrations of each drug or without drug as a control. Drug concentrations started at one-fourth of the MIC for the organism passaged, then increased to one-half of the MIC, MIC and 2× MIC by day 7. Populations from the terminal passage were spread onto LB agar, and individual colonies were tested for their susceptibility to antibiotics listed above, as well as moxifloxacin (Sigma #PHR1542) and ethidium bromide (Fisher #10042120). Following selection, five colonies from parental strains AL28 and AB18 were subjected to whole-genome sequencing (MicrobesNG), along with two colonies that had been passaged in nutrient broth only. Resulting sequences were compared to the appropriate parental strain.

Each whole-genome sequence was confirmed to be from the species expected using an average nucleotide identity (ANI) score above (>95%), and sequences were compared to both the ancestral strain and the cells passaged in nutrient broth only, using Snippy (v.4.6.0) to find sequence variants (29).

Measurement of twitching motility and growth

A previously described crystal violet assay was used to measure twitching motility in *A. baumannii* and *A. lwoffii* (30). Additionally, growth in LB and human serum (Merck #H4522) was measured. Full methods are listed in supplemental Text S2.

Scanning electron microscopy

Strains were grown overnight in LB, then diluted 1:50 for *A. baumannii* and 1:10 for *A. lwoffii* in LB because *A. lwoffii* grows to a lower final cell density than *A. baumannii*. Strains were grown to mid-log, washed with phosphate-buffered saline (Merck #D8537), and then resuspended in 2.5% glutaraldehyde (Sigma #354400) to fix. Cells were imaged on an Apreo 2 Scanning Electron Microscope (Thermo Fisher) at ×5,000, ×10,000, and ×25,000 magnification. Cell length analysis was performed in ImageJ (31), where the lengths of 100 randomly selected cells from each strain were measured.

Virulence in the *Galleria mellonella* model

Galleria mellonella larvae were injected ($n = 10$ larvae per condition, which was independently repeated four times) with 10^6 bacterial cells as previously described (32), and the number of live/dead larvae was quantified across 7 days.

Comparing the virulence in a macrophage cell line *in vitro*

Human monocyte THP-1 cell line (American Type Culture Collection TIB-202) was cultured in Roswell Park Memorial Institute Medium with GlutaMAX (Thermo Fisher #61870–010) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, #A5256701) at 37°C and 5% CO₂. THP-1 monocytes were differentiated to macrophages with medium containing 50 ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma #P1585) for 3 days. Cells were then left to rest for 2 days by replacing the differentiation medium with complete medium without PMA. Macrophages were infected as previously described (33), with a multiplicity of infection of 100. Extracellular bacteria were killed after 2 hours using gentamicin at either 100 µg/mL or at 1 mg/mL for AB05. Association, invasion, and proliferation (after 6 hours) were quantified. Association was determined by subtracting the number of intracellular bacteria (invasion) from the total number of bacteria associated with macrophages (and within macrophages).

RESULTS

A. Iwoffii is more susceptible to a broad range of antibiotics than *A. baumannii*

Data from the UKHSA shows that *A. Iwoffii* sp. isolated from patients in England were more susceptible than *A. baumannii* to gentamicin, ciprofloxacin, meropenem, and colistin (4). Therefore, we sought to determine if the same was true in our diverse strain collection for a range of antibiotics from different drug classes (Table 1). MICs were higher for *A. baumannii* than for *A. Iwoffii* for all compounds tested. EUCAST resistance breakpoints were only available for ciprofloxacin (>1 µg/mL), meropenem (>2 µg/mL), and gentamicin (>4 µg/mL) (17). *A. Iwoffii* was clinically susceptible in all instances, whereas for *A. baumannii*, all but one isolate was resistant to ciprofloxacin; three of six strains were resistant to meropenem; and all were resistant to gentamicin.

A. Iwoffii carries fewer ARGs than *A. baumannii*

To explain the differences in antibiotic sensitivity between *A. Iwoffii* and *A. baumannii*, whole-genome sequences were searched for the presence of ARGs using the CARD database. Following QC, there were 4,809 *A. baumannii* and 38 *A. Iwoffii* genome sequences. Across the *A. Iwoffii* genomes, 40 different ARGs were found, while 333 different ARGs were detected across *A. baumannii*. Due to the lack of available sequences for *A. Iwoffii*, to quantitatively compare the presence of ARGs between the two species, a random permutation was conducted, which subsampled 38 sequences (the same number as the population of *A. Iwoffii* sequences) from the *A. baumannii* population 100 times to create an average. *A. baumannii* encodes significantly more ARGs than *A. Iwoffii*

TABLE 1 MIC values for *A. baumannii* and *A. Iwoffii* (µg/mL)^a

Strain	AMP	CEF	CHL	CIP	CLI	ERY	FUS	GEN	MER	NOV	RIF	TET
AB05	512	>32	256	>32	128	32	128	1,024	0.5	16	16	128
AB18	64	16	128	1	64	16	128	4	0.25	8	4	1
AB19	8	32	128	>32	64	32	128	16	0.25	8	4	8
AB20	32	16	128	2	64	64	64	4	>16	16	4	>128
AB25	1,024	>32	256	>32	128	64	128	128	8	32	4	>128
AB27	1,024	16	128	>32	32	8	64	1,024	16	8	4	>128
AL04	<1	2	2	0.06	2	<0.5	16	<2	0.03	8	0.5	0.5
AL28	<1	1	1	0.06	1	0.5	4	<2	0.12	4	0.5	0.25
AL29	<1	2	1	0.06	2	0.5	8	<2	0.03	8	0.5	0.25
AL32	<1	1	1	0.03	4	0.5	8	<2	0.12	8	0.5	0.25
AL33	<1	1	1	0.06	4	0.5	8	<2	0.12	8	0.5	0.25

^aAMP, ampicillin; CEF, cefotaxime; CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; MER, meropenem; NOV, novobiocin; RIF, rifampicin; TET, tetracycline.

($P < 0.0001$); the mean number of ARGs in *A. Iwoffii* was 9 but was 30 in *A. baumannii* (Fig. 1a).

Although there was a difference in total gene presence, the classes of antibiotics that the ARGs were active against were similar across the two species (Fig. 1b). The majority of ARGs (>50%) found in *A. Iwoffii* and *A. baumannii* reduce the host’s susceptibility to beta lactams and aminoglycosides.

***A. Iwoffii* and *A. baumannii* possess similar genomic signatures of horizontal gene transfer, but *A. Iwoffii* contains more DNA defense systems**

The greater antibiotic resistance levels of *A. baumannii* are seemingly explained by the fact that this species harbors significantly more ARGs than *A. Iwoffii*. However, both species inhabit similar niches, cause similar types of infection, and therefore are expected to have been exposed to similar antibiotics. Variation in rates of horizontal gene transfer into and within each species might explain the difference in the numbers of ARGs they carry. To investigate this, the presence of prophage and plasmid-associated sequences, type IV pili genes for natural transformation, and the presence of DNA defense systems, which would limit the acquisition of foreign DNA, were searched for in the whole-genome sequences.

To determine whether *A. baumannii* and *A. Iwoffii* harbor different numbers or types of plasmids, ABRicate was used to screen for plasmid replicons from an *Acinetobacter* replication initiation (*rep*) gene database (25). An average of four and two *rep* genes were found per *A. Iwoffii* and *A. baumannii* genome, respectively. A random permutation and Welch’s *t*-test revealed that *A. Iwoffii* contained significantly more *rep* genes than *A. baumannii* ($P < 0.0001$), suggesting that *A. Iwoffii* harbors more plasmids (Fig. 2a).




FIG 1 *A. baumannii* encodes more ARGs than *A. Iwoffii*. (a) Number of ARGs found per whole-genome sequence from either species. *A. baumannii* in pink, $n = 4,809$, *A. Iwoffii* in yellow, $n = 38$. A random permutation and Welch’s *t*-test was performed to compare the average number of genes when the sample sizes were the same. **** $P < 0.0001$. (b) Stacked bar chart showing drug classes targeted by all antibiotic resistance genes found in *A. Iwoffii* and *A. baumannii* whole-genome sequences. Only 40 different ARGs were found for *A. Iwoffii*, whereas 333 different ARGs were found across *A. baumannii*, but this is likely explained by the different data set sizes of either species. EP, efflux pump-associated genes




FIG 2 Signatures of foreign DNA acquisition. (a) Number of *rep* genes found per whole-genome sequence from either species, (b) number of DNA defense system genes per sequence. *A. baumannii* in pink, $n = 4,809$, *A. Iwoffii* in yellow, $n = 38$. (c) The twitching motility of individual strains, (d) combined values of all strains tested per species, and (e) the number of type IV pili-associated genes found in the whole-genome sequences. A random permutation and Welch's *t*-test were used to compare the mean number of *rep*, DNA defense system, and type IV-associated genes in comparable data sets of *A. baumannii* and *A. Iwoffii*. *A. baumannii* genomes encode more genes than *A. Iwoffii* (in all instances, **** $P < 0.0001$).

Acinetobacter rep genes are classified broadly according to the protein family they encode [Rep_1, Rep_3 (R3), or RepPriCT_1] and specifically by homology (>95% nucleotide identity cut-off) to a collection of reference *rep* sequences (25). All *A. Iwoffii* *rep* genes detected here belonged to the R3 group. However, since the *rep* database was

constructed primarily for the purpose of typing plasmids in *A. baumannii*, there were inconsistencies when comparing the *rep* genes identified by ABRicate and the number of circular plasmid sequences in complete *A. lwoffii* genomes. ABRicate detected fewer *rep* genes ($n = 34$) than there were plasmids ($n = 64$) in the complete genomes (Table S3). While it is possible that some plasmids did not contain a recognizable *rep* gene, as has been reported for *A. baumannii* plasmids (25), this was unlikely to be the case for all instances here. Therefore, the NCBI annotations for all plasmids in complete *A. lwoffii* genomes were screened for ORFs labeled “rep,” and a further six genes not represented in the database were found, five encoding Rep_3 proteins [CP032104.1 (pALWEK1.11), CP080579.1 (pALWVS1.3), CP072552.1 (pH7-68), CP080580.1 (pALWVS1.4), and CP080643.1 (pALWEK1.16)] and one encoding Rep_1 [CP080641 (pALWEK1.14)]. In a phylogenetic tree, these genes clustered independently of previously known *rep* genes (Fig. S1). With these considered, all but one of the *A. lwoffii* *rep* genes clustered in R3, supporting the idea that *A. lwoffii* almost exclusively maintains R3-type plasmids.

The most common *rep* types in *A. lwoffii* were R3-T25/R3-T45, which were found in a total of 92% of genomes. R3-T25 and R3-T45 are 94.71% identical at the nucleotide level and therefore, although classed as different *rep* types using a 95% cut-off value, are very closely related. Therefore, we propose that R3-T25/R3-T45 replicons represent a native *A. lwoffii* plasmid family, found in almost all complete genome sequences of this species examined here. In contrast, R3-T25/R3-T45 replicons were only found in 0.4% of *A. baumannii* genomes. For *A. baumannii*, 38% of sequences contained R2-T1 and 37% encoded RP-T1 *rep* types. In total, *A. baumannii* had 82 distinct *rep* types, including from RP, R1, R2, and R3 groups. A full list of *rep* genes highlighted in both species can be found in Table S4.

In addition to ARGs, occasionally, plasmids may also carry genes for RND efflux pumps, which can export a wide range of structurally diverse compounds, including antibiotics (13), and can act as important mechanisms for antibiotic resistance. RND determinants have been seen in plasmids in *A. baumannii*, for example, pDETAB2 from a Chinese ICU patient isolate (34), and more recently in *A. lwoffii*, where AL_065, which was isolated from a hospital bed rail in Pakistan, harbored a plasmid encoding an RND transporter and periplasmic adaptor protein (35). This plasmid (CP078046.1, *rep* type R3-T25) is also found in *A. baumannii* and has the potential to disseminate RND efflux genes across *A. lwoffii* more broadly. The RND pump is closest in homology to AdeB (31) and may therefore represent the acquisition of an additional, adaptive RND pump, reducing the susceptibility of this strain to structurally different substrates than those exported by its native RND system: AdelJK (1).

To determine if the relative lack of ARGs in *A. lwoffii* could also be related to other mechanisms of HGT, we searched for the presence of prophage DNA within genomes of both species. Both *A. lwoffii* and *A. baumannii* had prophage DNA within their genomes, as determined by PHASTER (Table S5). Therefore, both species have been previously infected by phage and have the capacity to acquire novel DNA, such as ARGs, introduced by phages.

The number of DNA defense systems across the two species was determined as this could impact their acquisition and maintenance of foreign DNA. Using DefenseFinder, *A. lwoffii* genomes were found to encode between 3 and 24 defense systems per genome, which was significantly more than *A. baumannii* which had between 1 and 14 ($P \leq 0.0001$) (Fig. 2b). The types of defense systems present also differed. *A. lwoffii* encoded mostly type I and IV restriction modification systems, which cleave unmethylated DNA, whereas *A. baumannii* encodes more PsyrTA toxin antitoxin systems and antiphage systems, e.g., SspBCDE (Table S6).

Acinetobacter spp. can display twitching motility in laboratory conditions, which aids the natural transformation of DNA from the extracellular environment into the cell (24). Therefore, the ability of *A. lwoffii* and *A. baumannii* to twitch was measured. While there was strain variation in subsurface twitching motility, generally *A. lwoffii* twitched less (average of 0.6 cm) than *A. baumannii* (average of 2.5 cm) at 37°C (Fig. 2c and d),

suggesting that *A. lwoffii* may be less naturally competent than *A. baumannii*; however, twitching efficiency does not always translate to natural competence.

Natural transformation uses type IV pili genes, and therefore, we also looked for the presence of genes associated with type IV pili in both species (Fig. 2e). There were significantly more type IV-associated genes found in *A. baumannii* genomes compared to *A. lwoffii* genomes ($P < 0.001$, Table S7).

***A. baumannii* readily evolved resistance to meropenem, ciprofloxacin, and gentamicin, but *A. lwoffii* only evolved resistance to ciprofloxacin**

Since *A. lwoffii* has remained susceptible to antibiotics, we sought to determine whether it can evolve resistance to clinically relevant antibiotics *in vitro*. For context, we also included *A. baumannii*, which is well known to evolve drug resistance rapidly. To this end, selection experiments were set up, where susceptible strains were grown in the presence of increasing concentrations of meropenem, ciprofloxacin, or gentamicin. After 7 days, whole-genome sequencing was performed to characterize any genomic changes compared to the ancestral strain (Table S8). Sequencing accession codes can be found in Table S2, where the *A. baumannii* 18 ancestor BioSample was [SAMN32597910](#) and *A. lwoffii* 28 ancestor was already available on NCBI as [SAMEA50767168 \(GCA_900444925.1\)](#).




FIG 3 MIC fold change results and single-nucleotide polymorphism presence for strains evolved to grow in increasing concentrations of meropenem. “Ancestor” and “WT” (broth-only) controls are compared to individual “M” isolates from the terminal passage. AB18, *A. baumannii*, and AL28, *A. lwoffii*. An MIC fold change of 1 means the strain is as susceptible or more susceptible to the drug compared with the ancestor. M, mutant; WT, wild type.

A. baumannii (AB18) mutants selected in the presence of meropenem had meropenem MICs two- to threefold above that of the parent strain MIC, from 1 to 2–4 µg/mL (Table S8). There were also MIC increases for ampicillin (four- to fivefold), ciprofloxacin (threefold), and tetracycline (threefold), with some mutants also being less susceptible to moxifloxacin (two- to threefold) and erythromycin (two- to threefold) and erythromycin (two- to threefold) (Fig. 3). It was noted that fewer *A. lwoffii* (AL28) colonies were selected for; however, when MIC testing the mutants, the increase was also threefold above the ancestral MIC from 0.015 to 0.06 µg/mL. There was no significant MIC change for the other antibiotics tested.

Five mutants from AL28 and AB18 were subject to whole-genome sequencing, and their sequences were compared to the ancestral strain and parental strains, which had been passaged in the same experiment in nutrient broth only. Despite *A. lwoffii* being able to grow at the final concentration of meropenem used in the evolution experiment, no canonical resistance mutations were seen. In fact, no single-nucleotide polymorphisms (SNPs) were found in the mutants, even though the strains passaged in nutrient broth alone encoded some SNPs, indicating an adaptive physiological (rather than genetic) change. However, for *A. baumannii* (AB18), all five sequenced strains had SNPs in the RND efflux transporter encoding gene *adeJ* and in the gene that encodes the repressor protein for this system, *adeN*. Three of the *adeJ* mutations were within the distal binding pocket of the pump, where beta-lactams bind (1). Additionally, AB18




FIG 4 MIC fold change results and SNP presence for strains evolved to grow in increasing concentrations of ciprofloxacin. “Ancestor” and “WT” (broth-only) controls are compared to individual “M” isolates from the terminal passage. AB18, *A. baumannii*, and AL28, *A. lwoffii*. An MIC fold change of 1 means the strain is as susceptible or more susceptible to the drug compared with the ancestor. M, mutant; WT, wild-type.

mutant 5 had mutations in genes encoding penicillin-binding proteins 2 and 3, known to be involved in meropenem resistance (36).

For ciprofloxacin, both *A. baumannii* and *A. lwoffii* cultures evolved resistance to above the EUCAST breakpoint. In AB18, large MIC changes, between 9- and 10-fold higher than the ancestral strain, were seen for ciprofloxacin and moxifloxacin. Additionally, MIC increases were also observed for gentamicin (four- to fivefold) and erythromycin (threefold) in some mutants (AB18 M2, M3, and M5), and the tetracycline MIC was also elevated (threefold) in AB18 M2 and M3. Mutants selected in the presence of increasing concentrations of ciprofloxacin had mutations in both the target of the drug (*gyrA/gyrB/parC*) and RND efflux systems (*ade* pumps).

For *A. lwoffii*, in contrast to the results seen with meropenem, target site and efflux SNPs were seen in the AL28 mutants. It is also worth noting that the AL28 wild-type (WT) strains also harbored polymorphisms, despite being passaged in nutrient broth only. SNPs were found in genes such as *higA1*, encoding an antitoxin protein, and *yfdX2*, encoding a heat resistance protein. AL28 mutants had SNPs in *adeJ* (RND pump), *adeN* (RND pump regulator), *atpB* (ATP synthase), and *gyrA* and *gyrB* (genes coding for DNA gyrase). Presumably, the combination of SNPs in efflux-related genes and target-site genes contributed to the reduced susceptibility of the mutants to ciprofloxacin and moxifloxacin and also protected against meropenem (Fig. 4).

Since *A. lwoffii* seemed to be capable of evolving drug-resistance mutations to ciprofloxacin but not meropenem, a third experiment was conducted. Here, gentamicin was chosen which is also used clinically to treat *Acinetobacter* infections. All AB18 mutants had elevated MICs to gentamicin (eight or ninefold above the ancestral strain MIC), taking them from clinically susceptible to resistant (>4 µg/mL) (Fig. 5). These mutants also displayed a reduced susceptibility to ciprofloxacin and moxifloxacin, and some of the AB18 mutants (1, 2, and 4) also showed a reduced susceptibility to erythromycin and tetracycline too. The WT strains grown in broth did not encode any SNPs, whereas the mutant strains had SNPs in *adeB* (RND pump), *adeR*, *adeS* (genes for RND pump regulator), *fusA* (elongation factor B), *ptsP* (phosphoenolpyruvate protein phosphotransferase, which is important in sugar transport), and *tetR* (global regulator).

As with meropenem, the *A. lwoffii* strain tested did not exhibit drug resistance to gentamicin or other drugs tested. However, during this experiment many SNPs were selected in both the nutrient broth-only conditions (WT1 and WT2) and gentamicin conditions (M1–M5). Mutations found only in the AL28 cells grown in gentamicin included SNPs in *acr3* and *arsH* (arsenic resistance), *chrA* (chromate resistance), and *merA*, *merD*, *merR*, and *merT* (mercuric transport proteins). Therefore, there was both conservative MIC differences and genomic evidence of a stress response, particularly in metal-tolerance genes.

In summary, *A. baumannii* AB18 was able to evolve resistance in 7 days to three clinically relevant antibiotics, which provided elevated MICs not only to that antibiotic but also to drugs from other classes, such as fluoroquinolones, tetracyclines, aminoglycosides, and macrolides. Furthermore, AB18 went from clinically susceptible to resistant, as defined by EUCAST breakpoints, in each instance. However, for *A. lwoffii*, clinical resistance was seen only for ciprofloxacin. These results show that *A. lwoffii* has a more limited capacity to evolve resistance to antibiotics, and due to the diversity of efflux-related mutations in *A. baumannii*, this may be due to the lack of RND systems in *A. lwoffii*.

A. lwoffii* forms less biofilm, and the biofilm is more susceptible to antibiotics and biocides than those formed by *A. baumannii

Antibiotic susceptibility is known to be decreased when bacteria exist within a biofilm and *Acinetobacter* often forms biofilm to aid survival in the clinical environment (37). Therefore, the biofilm-forming capacity and susceptibility of biofilm to antibiotics were determined. In static conditions, *A. baumannii* strains formed significantly more biofilm on average than the *A. lwoffii* strains ($P < 0.001$), median OD₆₀₀ values of 3.39 and 0.53, respectively (Fig. S2a and b). However, when biofilm was formed under laminar flow




FIG 5 MIC fold change results and SNP presence for strains evolved to grow in increasing concentrations of gentamicin. “Ancestor” and “WT” (broth-only) controls are compared to individual “M” isolates from the terminal passage. AB18, *A. baumannii*, and AL28, *A. lwoffii*. An MIC fold change of 1 means the strain is as susceptible or more susceptible to the drug compared with the ancestor. M, mutant; WT, wild-type.

conditions, there was no significant difference in the amount of biofilm formed between the two species (Fig. S2c).

TABLE 2 MBEC^a and minimum broth inhibitory concentrations of antibiotics and biocides in *A. lwoffii* (AL04) and *A. baumannii* (AB20)

	AL04		AB20	
	MBEC	MIC	MBEC	MIC
Cefotaxime (µg/mL)	256	2	8192	16
Chlorhexidine (%)	0.0017	0.0008	<1	0.0035
Ciprofloxacin (µg/mL)	16	0.06	128	2
Meropenem (µg/mL)	0.06	0.03	<128	0.25
Oxacillin (µg/mL)	8	16	<4,096	512
Tetracycline (µg/mL)	256	0.5	1,024	2
Triclosan (µg/mL)	0.5	0.5	<128	1
Rifampicin (µg/mL)	8	0.5	64	4

^aMBEC, minimum biofilm eradication concentration.

When the genomes were searched, for genes previously associated with biofilm formation (26), *A. lwoffii* sequences were found to have a mean of one gene per sequence, whereas *A. baumannii* had a mean of eight genes per genome sequence (Fig. S2d; Table S9). In the case of *csuABC* pili genes, which mediate adhesion to human cells, >89% of *A. baumannii* sequences searched had all three of these genes, whereas they were all absent in the *A. lwoffii* genome sequences. However, as this database was created using genes from *A. baumannii*, biofilm-associated genes exclusive to or uncharacterized in *A. lwoffii* would not have been found using this approach.

Given that a biofilm lifestyle is associated with decreased susceptibility to antibiotics, the MIC and minimum biofilm eradication concentration (MBEC) was determined for representatives of both species (Table 2). For both species, the MBEC values were generally higher than the MIC values; for example, for AB20, the cefotaxime MBEC was 10-fold higher than the MIC. However, the effect was less evident in *A. lwoffii* (AL04), where there were instances where the MBEC and MIC values did not significantly change (chlorhexidine, meropenem, and triclosan). Furthermore, in general, the *A. lwoffii* (AL04) MBEC values were lower than those of *A. baumannii* (AB20). Therefore, while the biofilms formed by both strains were less susceptible to antibiotics and biocides, the biofilm formed by *A. baumannii* (AB20) afforded greater protection than that formed by *A. lwoffii*.




FIG 6 Average cell length (μM) of *A. baumannii* (AB) and *A. lwoffii* (AL) strains imaged by the Apreo 2 Scanning Electron Microscope. *A. lwoffii* had statistically longer cells than *A. baumannii* strains. **** $P \leq 0.0001$, one-way analysis of variance with Tukey's multiple comparisons. The whiskers on the box plot show minimum and maximum values obtained.

A. lwoffii* has a longer cell morphology than *A. baumannii

Thus far, it is clear that *A. lwoffii* is more susceptible to antibiotics than *A. baumannii* in both static and biofilm conditions, and this is likely due to a reduced ability to evolve and acquire resistance, which may be underpinned by the presence of more DNA defense systems and fewer RND efflux pumps. Given the lack of research into *A. lwoffii*, the basic biology of the two species under laboratory conditions was assessed.

To determine whether there were any morphological differences between these two species, two strains of *A. baumannii* (AB05 and AB18) and two strains of *A. lwoffii* (AL04 and AL28) were imaged using scanning electron microscopy. *A. lwoffii* had significantly longer cells than *A. baumannii* ($n = 100$ cell measurements per strain) (Fig. 6; Fig. S3).

A. baumannii* grows more readily in both LB and human serum than *A. lwoffii

Additionally, the growth of both species was compared at 37°C, 30°C, and 25°C. In LB, *A. lwoffii* grew to a lower final density than *A. baumannii* at all temperatures. Growing at cooler temperatures generally increased the length of the lag phase. The mean generation times (Table S10) were generally faster at 30°C for *A. lwoffii*, while *A. baumannii* grew fastest at 37°C. While *A. lwoffii* grew to a lower final optical density (OD) than *A. baumannii* (Fig. S4), the generation times of AL28, AL32, and AL33 grew at rates comparable to the *A. baumannii* strains.

Due to the capacity of both species to cause bacteremia in humans, we also sought to understand how well both species survive and grow in human serum. Growth was compared in human serum with and without complement proteins [normal human serum (NHS) and heat inactivated serum (HIS), respectively]; both species grew more slowly in serum than LB (Table S11; Fig. S5). Of the two *A. lwoffii* strains tested, AL04 had a prolonged lag but did grow in both HIS and NHS, although growth rate was better in HIS. AL28 did not grow in serum and formed clumps, making OD measurements problematic. *A. baumannii* AB05 and AB18 grew as well in normal serum and as they did in HIS. AB18 grew significantly ($P = 0.0098$) better than AB05 in HIS. All other conditions were not significantly different.

Survival in human serum was also measured to determine whether, although not actively growing, strains could remain viable in the presence of serum. All strains, except AL28, could survive in NHS, and by 24 hours, CFU per milliliter was similar in both the serum and the LB control (Fig. 7a).

A synthetic wound model (38) also showed that *A. lwoffii* strains did not grow as well as *A. baumannii* strains. This supports the fact that *A. lwoffii* survived poorly in the presence of human serum as AL04 and AL28 did not grow (Table S12).

***A. baumannii* is more virulent than *A. lwoffii* in vivo and in vitro**

We also sought to determine whether there was a difference in the *in vivo* virulence capacity of the two species and chose to use the well-characterized infection model organism, *Galleria mellonella*, which has an innate immune system (32). When *G. mellonella* larvae were infected with 1×10^6 *A. baumannii* or *A. lwoffii* cells, more larvae were killed when infected with *A. baumannii* (AB05 and AB18) than *A. lwoffii* (AL04 and AL28), which correlates with what has been seen previously (32). However, this was only statistically significant for AB05, *A. baumannii* AYE; AB05 was significantly more virulent than AB18 in this model (Fig. 7b; $P < 0.0001$, log-rank test). By 48 hours, the probability of larvae survival was <25% for AB05 infection, whereas it was >95% for AL28.

Since *A. baumannii* AYE was more virulent *in vivo* than *A. lwoffii*, we also probed the whole-genome sequences for the presence of virulence genes. *A. baumannii* genomes encoded significantly more virulence genes than *A. lwoffii* genomes ($P < 0.0001$; Fig. 7c; Table S13) when using a random permutation and *t*-test to compare two equally sized sample sets. As before, virulence genes have been mainly characterized in *A. baumannii*, and therefore, the database is biased to highlight virulence genes in *A. baumannii*.

Finally, to determine virulence *in vitro*, strains were incubated with a human macrophage cell line, THP-1. *A. baumannii* strains (AB05 and AB18) were able to attach to and subsequently invade THP-1 cells (Fig. 7d and e). However, after 6 hours, proliferation was also measured, and there was no difference in the number of CFUs between invasion




FIG 7 (a) The survival of AB and AL strains in both LB (dashed line) and normal human serum (continuous line) over 24 hours. (b) Survival of *Galleria mellonella* after inoculation with either AB (pink) or AL (yellow). A phosphate-buffered saline injury control is included in black. A log-rank test was conducted, where only AB05 was significantly more virulent than the other conditions ($P < 0.0001$). (c) The number of virulence-associated genes found in *A. baumannii* (pink) and *A. lwoffii* (yellow) whole-genome sequences ($****P < 0.0001$). A random permutation and Welch's *t*-test was used and shows that *A. baumannii* encodes significantly more virulence genes than *A. lwoffii*. Attachment (d), invasion (e), and proliferation (f) of both species in human THP-1 macrophages were measured. SE01 is a positive control of *Salmonella enterica* Typhimurium. Comparative statistics (one-way analysis of variance) were performed, but no conditions were significantly different. AB, *A. baumannii*; AL, *A. lwoffii*.

and proliferation, suggesting *A. baumannii* was not actively growing within the cells but could survive at least for the period of the assay (Fig. 7f). In contrast, neither of the *A. lwoffii* strains tested could attach to or invade human macrophage cells *in vitro*.

DISCUSSION

The emerging pathogen, *A. lwoffii*, is the leading cause of *Acinetobacter*-derived bloodstream infections in England and Wales, followed by the extensively studied *A. baumannii* (4). However, *A. baumannii* has developed widespread multidrug resistance, while *A. lwoffii* has remained sensitive to almost all antibiotics. While research into *A. baumannii* is increasing and more is known about its antibiotic resistance, there remains a knowledge gap in understanding the emerging opportunistic pathogen, *A. lwoffii*. This work aimed to explore differences in the two species in terms of their antibiotic susceptibility, infectivity, and basic biology. We have shown that *A. lwoffii* is more susceptible to drugs used to treat *Acinetobacter* infections than *A. baumannii*, is less virulent, and does not evolve drug resistance to the same degree as *A. baumannii*.

This work confirmed previous data suggesting *A. lwoffii* is susceptible to antibiotics, while *A. baumannii* is commonly multidrug resistant (4) and showed the difference in phenotype is caused by *A. lwoffii* encoding fewer resistance genes than *A. baumannii*. Both species are found in similar environments such as on the human body, although *A. baumannii* is not considered to be part of a healthy skin microbiome (6, 39). As they are both found within the hospital environment, it is peculiar that resistance (either by mutation or the horizontal acquisition of ARGs) has not been commonly selected for in *A. lwoffii*.

The lack of ARGs in *A. lwoffii* may be due, at least in part, to the presence of DNA defense systems that are absent in *A. baumannii*, such as a greater number of restriction modification systems. The presence of more DNA defense systems in *A. lwoffii* suggests that this species is more stringent about the DNA it maintains (40).

In addition to fewer ARGs, *A. lwoffii* also has less readily evolved resistance to three clinically relevant drugs compared to *A. baumannii*, following passage in increasing concentrations of antibiotics over the course of 7 days. We note that, while the growth rate of these organisms is similar, the total generation number may have differed slightly. However, the difference in resulting drug susceptibility is nevertheless significant. Drug-resistance mutations often occur in the drug's target: penicillin-binding proteins for meropenem (36), DNA gyrase for ciprofloxacin (41–43), and the ribosome for gentamicin (44). This was the case for *A. baumannii* here. In the one instance where *A. lwoffii* evolved resistance, to ciprofloxacin, drug target mutations were also observed. A limitation of using Snippy and short-read sequencing technology is that some genetic mutations may have been missed, for example, recombination and gene inversion events. Additionally, by working with the assemblies, we also were unable to search for gene amplification events. Ciprofloxacin mutations often occur in the quinolone resistance-determining regions (QRDR) of *GyrA*, *GyrB*, and *ParC* (43). The *A. baumannii* mutations in *gyrA* were in the QRDR (amino acids 65–104), but *A. baumannii* mutations in *parC* and *A. lwoffii* in *gyrB*, however, were not within the QRDRs.

Additionally, mutations were captured in RND efflux pumps that export the compounds used for selection. For example, *A. baumannii* meropenem mutants had *adeJ* mutations, and beta-lactams bind to the distal pocket of AdeJ (44, 45). Fluoroquinolones can be exported by all three Ade pumps in *A. baumannii* (39), which explains why mutations in all three Ade systems were seen, including mutations that affected the regulators of these systems. Gentamicin is exported by AdeB and can bind to both the proximal and distal binding pockets, but Y77, T91, and S134 are thought to be essential for gentamicin binding to the proximal pocket of AdeB (46). Given the proximity of the *A. baumannii* AdeB mutations (amino acids 97 and 136) in this study to those reported in the literature (46), it is likely that these mutations led to increased gentamicin export via AdeB. Mutations in AdeRS have been reported to increase AdeABC expression, for example, A91V in AdeR and A94V in AdeS (47). This study also captured the A91V SNP

in AdeR, which sits in the signal receiver domain, as well as other mutations in AdeRS, indicating that AdeRS may be being modulated to increase AdeABC expression and the extrusion of gentamicin.

The mutant evolution experiments clearly show that *A. lwoffii* has a reduced capacity to evolve resistance to antibiotics compared to *A. baumannii*, where it only evolved resistance to ciprofloxacin. This could be because *A. lwoffii* only encodes one tripartite RND system (AdeIJK) (1). Another example of a species with one tripartite RND system is *Neisseria gonorrhoeae*; however, in this organism, drug-resistance mutations and the acquisition of resistance genes are common (48). RND efflux pumps have an underpinning role in the development of resistance via other molecular mechanisms (44). For example, in other species of Gram-negative bacteria, deletion of efflux pumps reduces the mutation selection frequency (44, 49). In addition, mutations within efflux pumps often occur first evolutionarily and allow for the development of more canonical drug target mutations, which may have been the case in this study (50, 51). The reduced efflux capacity of *A. lwoffii* could therefore limit the selection of drug-resistance mutations. This is further supported by the fact that in *A. baumannii*, drug-resistance mutations were found across all three tripartite systems, indicating their important role in resistance evolution. Another potential mechanism for the lack of resistance development could be more stringent DNA repair mechanisms in *A. lwoffii*, for example mismatch repair to inhibit the recombination of non-homologous DNA. However, further work would be needed to confirm this (52).

When looking at infection-related phenotypes, *A. baumannii* was more virulent than *A. lwoffii* *in vitro*, and one of the *A. baumannii* strains was more virulent *in vivo*. It was already known that certain *A. baumannii* strains could infect macrophages and persist within their vacuoles, but this was the first time this experiment had been done using *A. lwoffii*, where none of the strains tested could persist within macrophages (33). This could indicate that it is easier to clear *A. lwoffii* infections. Both virulence potential and resistance to antibiotics have been linked with phase variation in *A. baumannii* AB5075, where opaque colonies were more drug resistant and virulent (53). While not observed in this study, *A. lwoffii* may also be able to undergo phase variation, which could affect their virulence and resistance phenotypes.

In summary, *A. lwoffii* is more susceptible to antibiotics than *A. baumannii* due to a lack of acquired and evolved resistance. Additionally, despite causing more bloodstream infections, the strains tested in this work were also less virulent than the *A. baumannii* strains. Therefore, the incidence of *A. lwoffii* bloodstream infections in the United Kingdom may be related to the increased opportunity of *A. lwoffii* (a skin commensal) to get inside the body and cause infections as opposed to *A. baumannii* and *A. calcoaceticus*, which are not considered commensals. Ultimately, an open question remains surrounding why *A. lwoffii* does not seem to be developing drug resistance in the clinic, and more work is needed to elucidate if this results from a lack of efflux systems and/or more stringent DNA repair and defense, or other factors. While the widespread antibiotic susceptibility of *A. lwoffii* allows for successful clinical outcomes, there are sporadic cases of drug-resistant *A. lwoffii*, highlighting the possibility that drug resistance could emerge (10, 54). It is, therefore, important to fully chart the development of this emerging pathogen to limit the development of drug resistance.

ACKNOWLEDGMENTS

The authors thank Dr. Rebecca Hall for help with evolution experiments, Dr. Chris Connor for the MASH R script, and Dr. Andrew Edwards for help with the serum experiments. The authors also thank Dr. Matthew Wand, Dr. Katherine Hardy, Dr. Benjamin Evans, and Dr. Jolinda Pollock for kindly sharing *Acinetobacter* strains.

E.M.D. is funded by the Wellcome Trust (222386/Z/21/Z).

E.M.D. and J.M.A.B. conceptualized and designed the study. E.M.D. carried out genotypic and phenotypic analyses. E.H. performed the Bioflux experiments and imaging. T.M. captured the electron microscopy images with help from L.S. B.C. helped

with tissue culture, and R.S.M. helped with mutant evolution protocols. R.A.M. performed the plasmid analysis. E.M.D. and J.M.A.B. wrote the manuscript with input from R.A.M., E.H., B.C., R.S.M., M.A.W., and E.M.F.

AUTHOR AFFILIATIONS

¹Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom

²Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, United Kingdom

³Centre for Electron Microscopy, University of Birmingham, Birmingham, United Kingdom

⁴School of Life Sciences, University of Warwick, Coventry, United Kingdom

⁵Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom

AUTHOR ORCID*s*

Elizabeth M. Darby  <http://orcid.org/0000-0002-6990-3537>

Emma Holden  <http://orcid.org/0000-0002-0811-1675>

Freya Harrison  <http://orcid.org/0000-0001-8449-5095>

Eva M. Frickel  <http://orcid.org/0000-0002-9515-3442>

Mark A. Webber  <http://orcid.org/0000-0001-9169-7592>

Jessica M. A. Blair  <http://orcid.org/0000-0001-6904-4253>

FUNDING

Funder	Grant(s)	Author(s)
Wellcome Trust (WT)	222386/Z/21/Z	Elizabeth M. Darby

AUTHOR CONTRIBUTIONS

Elizabeth M. Darby, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review and editing | Robert A. Moran, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing | Emma Holden, Data curation, Investigation, Methodology, Writing – review and editing | Theresa Morris, Data curation, Writing – review and editing | Freya Harrison, Data curation, Methodology, Writing – review and editing | Barbara Clough, Conceptualization, Methodology, Supervision, Writing – review and editing | Ross S. McInnes, Conceptualization, Methodology, Supervision, Writing – review and editing | Ludwig Schneider, Investigation, Writing – review and editing | Eva M. Frickel, Supervision | Mark A. Webber, Methodology, Supervision, Writing – review and editing | Jessica M. A. Blair, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review and editing

DATA AVAILABILITY

Whole-genome sequences were either publicly available and downloaded from National Center for Biotechnology Information (NCBI, <https://www.ncbi.nlm.nih.gov>) or obtained from strains sequenced in this study. Raw reads generated from this work can be found on NCBI under project accession number [PRJNA918592](https://www.ncbi.nlm.nih.gov/PRJNA918592).

ETHICS APPROVAL

This study did not require ethical approval.

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

Supplemental Text and Figures (mSphere00109-24-s0001.docx). Texts S1 and S2 and Figures S1-S5.

Supplemental Tables (mSphere00109-24-s0002.xlsx). Tables S1-S13.

REFERENCES

- Darby EM, Bavro VN, Dunn S, McNally A, Blair JMA. 2023. RND pumps across the genus *Acinetobacter*: AdeJK is the universal efflux pump. *Microb Genom* 9:mgen000964. <https://doi.org/10.1099/mgen.0.000964>
- World Health Organisation. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed.
- Giamarellou H, Antoniadou A, Kanellakopoulou K. 2008. *Acinetobacter baumannii*: a universal threat to public health? *Int J Antimicrob Agents* 32:106–119. <https://doi.org/10.1016/j.ijantimicag.2008.02.013>
- United Kingdom Health Security Agency. 2021. Laboratory surveillance of *Acinetobacter* spp. bacteraemia in England 2020.
- Vincent J-L. 2009. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 302:2323. <https://doi.org/10.1001/jama.2009.1754>
- Patil JR, Chopade BA. 2001. Distribution and *in vitro* antimicrobial susceptibility of *Acinetobacter* species on the skin of healthy humans. *Natl Med J India* 14:204–208.
- Ku SC, Hsueh PR, Yang PC, Luh KT. 2000. Clinical and microbiological characteristics of bacteremia caused by *Acinetobacter lwoffii*. *Eur J Clin Microbiol Infect Dis* 19:501–505. <https://doi.org/10.1007/s100960000315>
- Chatterjee S, Datta S, Roy S, Ramanan L, Saha A, Viswanathan R, Som T, Basu S. 2016. Carbapenem resistance in *Acinetobacter baumannii* and other *Acinetobacter* spp. causing neonatal sepsis: focus on NDM-1 and its linkage to ISAba125. *Front Microbiol* 7. <https://doi.org/10.3389/fmicb.2016.01126>
- Mittal S, Sharma M, Yadav A, Bala K, Chaudhary U. 2015. *Acinetobacter lwoffii* an emerging pathogen in neonatal ICU. *Infect Disord Drug Targets* 15:184–188. <https://doi.org/10.2174/1871526515666150826114745>
- Nakwan N, Wannaro J, Nakwan N. 2011. Multidrug-resistant *Acinetobacter lwoffii* infection in neonatal intensive care units. *RRN* 2011:1–4. <https://doi.org/10.2147/RRN.S15964>
- Jawad A, Snelling AM, Heritage J, Hawkey PM. 1998. Exceptional desiccation tolerance of *Acinetobacter radioresistens*. *J Hosp Infect* 39:235–240. [https://doi.org/10.1016/s0195-6701\(98\)90263-8](https://doi.org/10.1016/s0195-6701(98)90263-8)
- Manian FA, Griesenauer S, Senkel D, Setzer JM, Doll SA, Perry AM, Wiechens M. 2011. Isolation of *Acinetobacter baumannii* complex and methicillin-resistant *Staphylococcus aureus* from hospital rooms following terminal cleaning and disinfection: can we do better? *Infect Control Hosp Epidemiol* 32:667–672. <https://doi.org/10.1086/660357>
- Colclough AL, Alav I, Whittle EE, Pugh HL, Darby EM, Legood SW, McNeil HE, Blair JM. 2020. RND efflux pumps in Gram-negative bacteria; regulation, structure and role in antibiotic resistance. *Future Microbiol* 15:143–157. <https://doi.org/10.2217/fmb-2019-0235>
- Nishino K, Latifi T, Groisman EA. 2006. Virulence and drug resistance roles of multidrug efflux systems of *Salmonella enterica* serovar Typhimurium. *Mol Microbiol* 59:126–141. <https://doi.org/10.1111/j.1365-2958.2005.04940.x>
- Alav I, Sutton JM, Rahman KM. 2018. Role of bacterial efflux pumps in biofilm formation. *J Antimicrob Chemother* 73:2003–2020. <https://doi.org/10.1093/jac/dky042>
- Andrews JM. 2001. The development of the BSAC standardized method of disc diffusion testing. *J Antimicrob Chemother* 48 Suppl 1:29–42. https://doi.org/10.1093/jac/48.suppl_1.29
- European Society of Clinical Microbiology and Infectious Diseases. 2023. MIC determination.
- Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Pribelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 19:455–477. <https://doi.org/10.1089/cmb.2012.0021>
- Mikheenko A, Pribelski A, Saveliev V, Antipov D, Gurevich A. 2018. Versatile genome assembly evaluation with QUAST-LG. *Bioinformatics* 34:i142–i150. <https://doi.org/10.1093/bioinformatics/bty266>
- Jain C, Rodriguez-R LM, Phillippy AM, Konstantinidis KT, Aluru S. 2018. High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. *Nat Commun* 9:5114. <https://doi.org/10.1038/s41467-018-07641-9>
- Ondov BD, Treangen TJ, Mellsted P, Mallonee AB, Bergman NH, Koren S, Phillippy AM. 2016. Mash: fast genome and metagenome distance estimation using MinHash. *Genome Biol* 17:132. <https://doi.org/10.1186/s13059-016-0997-x>
- Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. 2015. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. *Genome Res* 25:1043–1055. <https://doi.org/10.1101/gr.186072.114>
- Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen A-LV, Cheng AA, Liu S, et al. 2020. CARD 2020: antibiotic resistance surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Research*. <https://doi.org/10.1093/nar/gkz935>
- Leong CG, Bloomfield RA, Boyd CA, Dornbusch AJ, Lieber L, Liu F, Owen A, Slay E, Lang KM, Lostroh CP. 2017. The role of core and accessory type IV pilus genes in natural transformation and twitching motility in the bacterium *Acinetobacter baylyi*. *PLoS One* 12:e0182139. <https://doi.org/10.1371/journal.pone.0182139>
- Lam MMC, Koong J, Holt KE, Hall RM, Hamidian M. 2023. Detection and typing of plasmids in *Acinetobacter baumannii* using rep genes encoding replication initiation proteins. *Microbiol Spectr* 11:e0247822. <https://doi.org/10.1128/spectrum.02478-22>
- Hamidian M, Maharjan RP, Farrugia DN, Delgado NN, Dinh H, Short FL, Kostoulas X, Peleg AY, Paulsen IT, Cain AK. 2022. Genomic and phenotypic analyses of diverse non-clinical *Acinetobacter baumannii* strains reveals strain-specific virulence and resistance capacity. *Microb Genom* 8:000765. <https://doi.org/10.1099/mgen.0.000765>
- Arndt D, Grant JR, Marcu A, Sajed T, Pon A, Liang Y, Wishart DS. 2016. PHASTER: a better, faster version of the PHAST phage search tool. *Nucleic Acids Res* 44:W16–21. <https://doi.org/10.1093/nar/gkw387>
- Tesson F, Hervé A, Mordret E, Touchon M, d'Humières C, Cury J, Bernheim A. 2022. Systematic and quantitative view of the antiviral arsenal of prokaryotes. *Nat Commun* 13:2561. <https://doi.org/10.1038/s41467-022-30269-9>
- Seemann T. 2020. Snippy (4.6.0).
- Biswas I, Machen A, Mettlach J. 2019. *In vitro* motility assays for *Acinetobacter* species. *Methods Mol Biol* 1946:177–187. https://doi.org/10.1007/978-1-4939-9118-1_17
- Rasband WS. ImageJ (1.52). National Institutes of Health, Bethesda, Maryland.
- Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E. 2009. *Galleria mellonella* as a model system to study *Acinetobacter baumannii* pathogenesis and therapeutics. *Antimicrob Agents Chemother* 53:2605–2609. <https://doi.org/10.1128/AAC.01533-08>
- Sycz G, Di Venanzio G, Distel JS, Sartorio MG, Le N-H, Scott NE, Beatty WL, Feldman MF. 2021. Modern *Acinetobacter baumannii* clinical isolates

- replicate inside spacious vacuoles and egress from macrophages. *PLoS Pathog* 17:e1009802. <https://doi.org/10.1371/journal.ppat.1009802>
34. Liu H, Moran RA, Chen Y, Doughty EL, Hua X, Jiang Y, Xu Q, Zhang L, Blair JMA, McNally A, van Schaik W, Yu Y. 2021. Transferable *Acinetobacter baumannii* plasmid pDETAB2 encodes OXA-58 and NDM-1 and represents a new class of antibiotic resistance plasmids. *J Antimicrob Chemother* 76:1130–1134. <https://doi.org/10.1093/jac/dkab005>
 35. Naidu V, Shah B, Maher C, Paulsen IT, Hassan KA. 2023. AadT, a new weapon in *Acinetobacter*'s fight against antibiotics. *Microbiology* 169. <https://doi.org/10.1099/mic.0.001341>
 36. Sumita Y, Fukasawa M. 1995. Potent activity of meropenem against *Escherichia coli* arising from its simultaneous binding to penicillin-binding proteins 2 and 3. *J Antimicrob Chemother* 36:53–64. <https://doi.org/10.1093/jac/36.1.53>
 37. Longo F, Vuotto C, Donelli G. 2014. Biofilm formation in *Acinetobacter baumannii*. *New Microbiol* 37:119–127.
 38. Werthén M, Henriksson L, Jensen PØ, Sternberg C, Givskov M, Bjarnsholt T. 2010. An *in vitro* model of bacterial infections in wounds and other soft tissues. *APMIS* 118:156–164. <https://doi.org/10.1111/j.1600-0463.2009.02580.x>
 39. Kornelsen V, Kumar A. 2021. Update on multidrug resistance efflux pumps in *Acinetobacter* spp. *Antimicrob Agents Chemother* 65:10–1128. <https://doi.org/10.1128/AAC.00514-21>
 40. Vasu K, Nagaraja V. 2013. Diverse functions of restriction-modification systems in addition to cellular defense. *Microbiol Mol Biol Rev* 77:53–72. <https://doi.org/10.1128/MMBR.00044-12>
 41. Pan X-S, Ambler J, Mehtar S, Fisher LM. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 40:2321–2326. <https://doi.org/10.1128/AAC.40.10.2321>
 42. Bansal S, Tandon V. 2011. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in *Escherichia coli* clinical isolates. *Int J Antimicrob Agents* 37:253–255. <https://doi.org/10.1016/j.ijantimicag.2010.11.022>
 43. Attia NM, Elbaradei A. 2019. Fluoroquinolone resistance conferred by gyrA, parC mutations, and AbaQ efflux pump among *Acinetobacter baumannii* clinical isolates causing ventilator-associated pneumonia. *Acta Microbiol Immunol Hung* 67:234–238. <https://doi.org/10.1556/030.66.2019.040>
 44. Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, Blair JMA. 2023. Molecular mechanisms of antibiotic resistance revisited. *Nat Rev Microbiol* 21:280–295. <https://doi.org/10.1038/s41579-022-00820-y>
 45. Blair JMA, Bavro VN, Ricci V, Modi N, Cacciotto P, Kleinekathöfer U, Ruggerone P, Vargiu AV, Baylay AJ, Smith HE, Brandon Y, Galloway D, Piddock LJV. 2015. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity. *Proc Natl Acad Sci U S A* 112:3511–3516. <https://doi.org/10.1073/pnas.1419939112>
 46. Su C-C, Morgan CE, Kambakam S, Rajavel M, Scott H, Huang W, Emerson CC, Taylor DJ, Stewart PL, Bonomo RA, Yu EW. 2019. Cryo-electron microscopy structure of an *Acinetobacter baumannii* multidrug efflux pump. *mBio* 10:10–1128. <https://doi.org/10.1128/mBio.01295-19>
 47. Lari AR, Ardebili A, Hashemi A. 2018. AdeR-AdeS mutations & overexpression of the AdeABC efflux system in ciprofloxacin-resistant *Acinetobacter baumannii* clinical isolates. *Indian J Med Res* 147:413–421. https://doi.org/10.4103/ijmr.IJMR_644_16
 48. Unemo M, Shafer WM. 2011. Antibiotic resistance in *Neisseria gonorrhoeae*: origin, evolution, and lessons learned for the future. *Ann N Y Acad Sci* 1230:E19–28. <https://doi.org/10.1111/j.1749-6632.2011.06215.x>
 49. McNeil HE, Alav I, Torres RC, Rossiter AE, Laycock E, Legood S, Kaur I, Davies M, Wand M, Webber MA, Bavro VN, Blair JMA. 2019. Identification of binding residues between periplasmic adapter protein (PAP) and RND efflux pumps explains PAP-pump promiscuity and roles in antimicrobial resistance. *PLoS Pathog* 15:e1008101. <https://doi.org/10.1371/journal.ppat.1008101>
 50. Silva KPT, Sundar G, Khare A. 2023. Efflux pump gene amplifications bypass necessity of multiple target mutations for resistance against dual-targeting antibiotic. *Nat Commun* 14:3402. <https://doi.org/10.1038/s41467-023-38507-4>
 51. Papkou A, Hedge J, Kapel N, Young B, MacLean RC. 2020. Efflux pump activity potentiates the evolution of antibiotic resistance across *S. aureus* isolates. *Nat Commun* 11:3970. <https://doi.org/10.1038/s41467-020-17735-y>
 52. Harfe BD, Jinks-Robertson S. 2000. DNA mismatch repair and genetic instability. *Annu Rev Genet* 34:359–399. <https://doi.org/10.1146/annurev.genet.34.1.359>
 53. Tipton KA, Dimitrova D, Rather PN. 2015. Phase-variable control of multiple phenotypes in *Acinetobacter baumannii* strain AB5075. *J Bacteriol* 197:2593–2599. <https://doi.org/10.1128/JB.00188-15>
 54. Paul R, Ray J, Mondal S, Mondal J. 2016. A case of community-acquired multi-drug resistant *Acinetobacter lwoffii* bacteremia. *J Med Soc* 30:128. <https://doi.org/10.4103/0972-4958.182926>